

1 **Tract-based white matter hyperintensity patterns in patients with Systemic Lupus**
2 **Erythematosus using an unsupervised machine learning approach.**

3
4 Theodor Rumetshofer^{*1†}, Francesca Inglese^{2†}, Jeroen de Bresser², Peter Mannfolk³, Olof
5 Strandberg⁴, Andreas Jönsen⁵, Anders Bengtsson⁵, Markus Nilsson¹, Linda Knutsson^{6,7,8},
6 Jimmy Lätt³, Gerda M. Steup-Beekman⁹, Tom W.J. Huizinga⁹, Mark A. van Buchem², Itamar
7 Ronen^{10,‡} and Pia C. Sundgren^{1,3,11,‡}

8
9 ¹*Department of Clinical Sciences Lund/Diagnostic Radiology, Lund University, Lund, Sweden*

10 ²*Department of Radiology, Leiden University Medical Center, Leiden, Netherlands*

11 ³*Department of Medical Imaging and Physiology, Skåne University Hospital, Lund, Sweden*

12 ⁴*Department of Clinical Sciences Malmö/ Clinical Memory Research Unit, Lund University,*
13 *Lund, Sweden*

14 ⁵*Department of Clinical Sciences Lund/ Rheumatology, Lund University, Skåne University*
15 *Hospital, Lund, Sweden*

16 ⁶*Department of Medical Radiation Physics, Lund University, Lund, Sweden*

17 ⁷*Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins*
18 *University School of Medicine, Baltimore, MD, US*

19 ⁸*F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Research*
20 *Institute, Baltimore, MD, US.*

21 ⁹*Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands*

22 ¹⁰*Clinical Imaging Science Center, Brighton and Sussex Medical School, University of*
23 *Brighton, UK*

24 ¹¹*Lund University BioImaging Center, Lund University, Lund, Sweden*

25
26 *Correspondence:

27 Theodor Rumetshofer

28 theodor.rumetshofer@med.lu.se

29 ORCID: 0000-0002-0778-0703

30
31 † T Rumetshofer and F Inglese have contributed equally to this work and share first
32 authorship

33 ‡ I Ronen and PC Sundgren have contributed equally to this work and share senior
34 authorship.

35
36
37 **KEYWORDS**

38 Magnetic resonance imaging, Cluster analysis, White matter hyperintensities, Systemic lupus
39 erythematosus, Rare diseases

40
41
42 **FORMAT**

43 Article

46 **ABSTRACT**

47

48 Currently, little is known about the spatial distribution of white matter hyperintensities (WMH)
49 in the brain of patients with Systemic Lupus erythematosus (SLE). Previous lesion markers,
50 such as number and volume, ignore the strategic location of WMH. The goal of this work was
51 to develop a fully-automated method to identify predominant patterns of WMH across WM
52 tracts based on cluster analysis. A total of 221 SLE patients with and without neuropsychiatric
53 symptoms from two different sites were included in this study. WMH segmentations and lesion
54 locations were acquired automatically. Cluster analysis was performed on the WMH
55 distribution in 20 WM tracts. Our pipeline identified five distinct clusters with predominant
56 involvement of the forceps major, forceps minor, as well as right and left anterior thalamic
57 radiations and the right inferior fronto-occipital fasciculus. The patterns of the affected WM
58 tracts were consistent over the SLE subtypes and sites. Our approach revealed distinct and
59 robust tract-based WMH patterns within SLE patients. This method could provide a basis, to
60 link the location of WMH with clinical symptoms. Furthermore, it could be used for other
61 diseases characterized by presence of WMH to investigate both the clinical relevance of WMH
62 and underlying pathomechanism in the brain.

63

64

65

66 1. INTRODUCTION

67 White matter hyperintensities (WMH) are lesions in the white matter (WM) appearing
68 hyperintense on T₂-weighted MRI images¹. The prevalence of WMH in the general population
69 increases with age¹. WMH are considered as important neuroimaging and clinical markers in
70 many neurological diseases². However, the pathogenesis of WMH is not well understood and
71 may have various etiologies. The prevalence of WMH is highly variable within and across
72 different diseases^{2,3}. WMH are one of the main imaging findings observed in the brain in
73 systemic lupus erythematosus (SLE) patients⁴, even though not all SLE patients manifest
74 WMH^{5,6}. SLE is a rare autoimmune disease affecting mostly women and it is characterized by
75 the production and deposition of several autoantibodies. SLE involves different organs,
76 including the central nervous system, in which damage could lead to neuropsychiatric (NP)
77 syndromes⁶. The American College of Rheumatology (ACR) describes 19 NP syndromes
78 that could be present in SLE patients. These ACR criteria also subdivide SLE patients
79 experiencing NP events in two subgroups based on the attribution of NP events directly related
80 to the disease (NPSLE) or other causes (non-NPSLE)^{7,8}. In clinical practice, however, the
81 attribution process of the NP events to the disease is difficult as the nature of NP syndromes is
82 highly heterogeneous and ranges from mild (e.g. headache and anxiety) to major symptoms
83 (e.g. seizures and psychosis)⁹. In addition, there are large differences in the NP attribution
84 across sites and across studies (between 37% and 95%)⁴, illustrating the difficulty in
85 establishing a rigorous standard for the attribution of NP to SLE¹⁰. We used the term NPSLE
86 to refer to patients with NP manifestations attributed to SLE and the term non-NPSLE to
87 patients with NP manifestations not attributed to SLE.

88
89 The origin of WMH in SLE is not fully understood, but could be the result of inflammatory and
90 immunologically mediated small vessel disease (SVD)³. The location of WMH in white matter
91 has been shown to be of major importance in several neurological diseases. In multiple sclerosis
92 (MS) and Alzheimer's disease it has been demonstrated that WMH location is more strongly
93 linked to neuropsychological impairment than WMH volume and count^{11,12,13}. WMH location
94 in patients with arterial diseases can provide prognostic survival information¹⁴. WMH in SLE
95 patients has not been shown to be homogeneous across subgroups¹⁵. One study reported that
96 the prevalence of WMH in the splenium of the corpus callosum, in the right superior
97 longitudinal fasciculus and in some small clusters in the right corona radiata was higher in
98 NPSLE patients compared to SLE patients without NP involvement¹⁶. Another study reported
99 high WMH burden in the superior longitudinal fasciculus and anterior corona radiata in NPSLE
100 as well as in SLE patients without NP involvement¹⁷. All previous assessments of WMH burden
101 on specific white matter tracts in SLE were based on manual WMH segmentation. Although
102 manual segmentation is often considered as gold standard, it inevitably introduces variability
103 that can be reduced by devising an automated WMH segmentation pipeline^{18,19}. The variability
104 in results obtained from WMH segmentation algorithms compared to manual segmentation,
105 seems to depend on WMH burden. However, existing WMH segmentation algorithms are
106 robust for a wide range of WMH load^{20,21,22} and a fully automated pipeline could increase the
107 level of reproducibility.

108
109 The goal of our retrospective cross-sectional study was to develop a fully automated method to
110 characterize the spatial distribution of WMH across WM tracts in SLE patients. Due to the well-
111 known heterogeneity in diagnosis and difficulties in the attribution of NP manifestations, we
112 aimed for a highly objective approach by investigating only the spatial distribution of WMH in
113 the brain. We used an unsupervised machine learning method to identify clusters based on WM
114 tract-based abnormalities. We addressed the typical paucity of subjects in SLE studies by

115 pooling two cohorts of SLE patients. Further, we investigated if our method is robust across
116 SLE subgroups and clinical and radiological differences between the sites.

117

118

119 2. METHODS

120 2.1 Subject population

121 2.1.1 Leiden cohort

122 The Leiden University Medical Center (LUMC) is the national referral center in the
123 Netherlands for SLE patients experiencing NP symptoms. The SLE patients undergo a one-day
124 standardized evaluation that includes multidisciplinary medical assessments and
125 complementary tests, including extensive laboratory tests, neuropsychological testing and a
126 brain MRI scan^{23,24}. All patients are assessed by a rheumatologist, neurologist, psychiatrist,
127 vascular internal medicine expert and advanced nurse practitioner. This evaluation is followed
128 by a multidisciplinary consensus meeting in order to decide whether the NP events are
129 attributable to SLE or not. In the final attribution of NP symptoms to SLE or other etiologies,
130 several aspects are taken into account: the time between the onset of NP symptoms and
131 diagnosis of SLE, SLE disease activity, the type of NP symptoms, favoring factors and the
132 presence of alternative diagnoses^{10,25}. NPSLE diagnoses were defined according to the 1999
133 ACR nomenclature²⁶. All patients fulfilled the 1997 revised ACR criteria for the classification
134 of SLE²⁷.

135 From this cohort, 216 patients scanned between May 2007 and April 2015 were eligible.
136 Information on sex, age, disease duration and age of disease onset was obtained via interview
137 with the patient and retrieved from electronic medical records. SLE activity and damage
138 indices were scored for each patient: the SLE disease activity was determined using the
139 Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)²⁸; SLE irreversible
140 damage was assessed with the Systemic Lupus International Collaborating Clinics/American
141 College of Rheumatology damage index (SDI)⁸. The Leiden-The Hague-Delft ethics approval
142 committee approved the study (registration number P07.177) and all included patients signed
143 informed consent.

144 All participants were scanned using a Philips Achieva 3T MRI scanner (Philips Healthcare,
145 Best, The Netherlands) equipped with a body transmit RF coil and an 8-Channel receive head
146 coil array. A standardized scanning protocol was used. The sequences included in this study
147 were: a 3D T₁-weighted scan (voxel size = 1.17 × 1.17 × 1.2 mm³; TR/TE = 9.8/4.6 ms) and two
148 versions of a fluid-attenuated inversion recovery (FLAIR) scan. A total of 99 data sets included
149 a 2D-multislice FLAIR sequence (voxel size = 1.0 × 1.0 × 3.6 mm³;
150 TR/TE/TI = 10000/120/2800 ms) and 53 data sets included a 3D FLAIR (voxel
151 size = 1.10 × 1.11 × 0.56 mm³; TR/TE/TI = 4800/576/1650 ms) (see Supplementary Table S1
152 for a summary of the MRI methods). The change from 2D to 3D in the FLAIR protocol occurred
153 in February 2013.

154 2.1.2 Lund cohort

156 SLE patients experiencing NP symptoms were recruited by the Department of Rheumatology
157 in Lund, Skåne University Hospital, Sweden. Inclusion criteria were: female sex, age between
158 18 and 55 years and right handedness. Patients with any contraindication to MRI or pregnancy
159 were not asked to participate in this study. All patients fulfilled the SLICC classification criteria
160 for SLE²⁹. Extensive laboratory and neuropsychological testing were performed in the Lund
161 cohort as well. The brain MRI scan was performed on the same day as the clinical visit with
162 few exceptions due to logistical issues (maximum of 2 weeks in difference, e.g. patients
163 requested another time slot). The collected clinical data and the NP symptoms, as defined by
164 the American College of Rheumatology (ACR) case definition for NPSLE²⁶, were evaluated by
165 a rheumatologist and a neurologist. In case of split opinions, a consensus meeting followed.
166 In the Lund cohort, 73 subjects, recruited consecutively from January 2013 to January 2016,
167 were eligible for this study. All participants underwent rheumatologic and standardized
168 neurologic clinical assessment. Information about SLE disease activity and organ damage were

169 recorded according to the SLE disease Activity Index 2000 (SLEDAI-2k)²⁸ and the Systemic
170 Lupus Erythematosus International Collaborating Clinics / ACR Damage Index (SLICC/ACR-
171 DI)⁸. The Regional Ethical Review Board in Lund, Sweden (#2012/4, #2014/748) approved
172 this study and a written informed consent was obtained for all subjects prior to inclusion.
173 All participants underwent a brain scan on a 3T MRI Siemens scanner (Siemens MAGNETOM
174 Skyra, Erlangen, Germany). Imaging protocols included in this study were: T₁-weighted
175 magnetization-prepared rapid gradient-echo (MPRAGE) (1 mm isotropic voxels, TR/TE =
176 1900/2.54 ms) and 2D-multislice T₂-weighted FLAIR (0.7x0.7x3.0 mm, TR/TE/TI =
177 9000/81/2500 ms) (see Supplementary Table S1).

178 179 **2.2 Cluster analysis**

180 The preprocessing of image data, prior to cluster analysis is shown in Figure 1. A detailed
181 description of all preprocessing steps can be found in the Supplementary Material (Material
182 Section). For the cluster analysis, the WMH burden on each WM tract was L2-normalized (unit
183 norm) to obtain an individual WMH pattern for each subject. All subjects were included in this
184 analysis without giving any information about clinical diagnose, site or NP manifestations.
185 Hierarchical clustering (Ward's method)³⁰ was applied to the L2-normalized WMH load from
186 20 WM tracts (based on the JHU WM atlas) and a total of 186 SLE patients, resulting in 186
187 feature vectors with 20 values. SLE patients without detectable WMH (n=35) were not included
188 in the clustering but were included in the statistics. The cluster analysis and the performance
189 evaluation of the clustering procedure was performed with scikit-learn 0.20.3
190 (RRID:SCR_002577)³¹.

191 Agglomerative hierarchical clustering successively merges groups of subjects (starting with
192 each subject in its own group) based on the Euclidean distance between their WMH feature
193 vector, until all subjects form a single cluster. The successive merging of subgroups results in
194 a tree structure, or *dendrogram*, shown in Supplementary Figure S1. The iterative calculation
195 of inter-cluster distances was computed using Ward's method, resulting in minimal intra-cluster
196 variance. Each node or branching point of the tree corresponds to the merging of two clusters,
197 for which the corresponding inter-cluster distance is shown on the y-axis. To estimate the
198 optimal number of clusters, the dendrogram has to be cut at a certain distance threshold. The
199 optimal cluster number was evaluated by a consensus of two different methods: Silhouette
200 Coefficient³² and the Calinski-Harabasz index³³.

201 To evaluate the robustness of the method, three sensitivity analyses were performed. In the first
202 one, cluster analysis was performed on each SLE subgroup. The second sensitivity analysis was
203 implemented separately on the Lund and Leiden cohorts. The last sensitivity analysis was
204 performed by clustering the total SLE patients using as a regressor the site (Lund, Leiden)
205 including: sex, type of FLAIR (2D, 3D), age, disease duration, SDI-score, SLEDAI-2k-score,
206 and WMH total volume.

207 208 **2.3 Statistical analysis**

209 The between-group and cohort differences in demographic and clinical data, were assessed for
210 nominal variables with Chi-square test and for continuous variables based on their non-normal
211 distribution with Mann-Whitney U test. Differences between clusters were estimated for
212 nominal variables with Chi-square test and for continuous variables with non-parametric
213 Kruskal-Wallis test. Post-hoc pairwise comparisons of the clusters were performed with Mann-
214 Whitney U-test and using Bonferroni multiple comparison correction. Data are represented as
215 number (percentage) or median (10-90 percentile). All statistical analyses as well as tests for
216 distribution normality (D'Agostino and Pearson's test) were performed using Python package
217 Scipy 1.2.1 (RRID:SCR_008058)³⁴. Covariates correction was performed with a general linear
218 model (GLM) using Python package statsmodels 0.10.1 (RRID:SCR_016074)³⁵.

219 **3. RESULTS**

220 **3.1 Demographic and clinical data**

221 From the Leiden cohort, 216 patients were eligible for this study. Of these, 28 patients were
222 excluded because of undefined and mixed subgroups, 8 for misdiagnosis established during a
223 follow-up visit, 3 patients for motion artefacts in the MRI scans, 3 patients for co-registration
224 failure of the T1 and FLAIR images using the LST-LGA toolbox, 20 patients for the presence
225 of brain infarcts over 1.5 cm that hindered accurate brain volume measurements and 2 patients
226 were removed due to the presence of other diseases (brain tumor and large arachnoid cyst). This
227 resulted in a total of 152 patients included in the present study, comprising 37 NPSLE and 115
228 non-NPSLE patients.

229 From the Lund cohort, 73 subjects were eligible for this study. A total of 4 subjects were
230 excluded due to misdiagnosis, temporal lobe resection, hypothyroidism and co-registration
231 failure of the LST-LGA toolbox. In total, 69 patients were included in the present study,
232 comprising 42 NPSLE and 27 non-NPSLE.

233 Table 1 shows clinical and demographic data of the two different cohorts (Leiden/NL and
234 Lund/SWE). Statistically significant differences were observed in sex, age, disease duration,
235 age of onset, SLE disease scores, ACR criteria, volume and number of WMH ($p < 0.05$).

236 An overview of the cerebrovascular risk factors, ongoing pharmacologic treatments as well as
237 antibodies can be found in Supplementary Table S2.

238 From both cohorts, a total of 221 data sets were analyzed in this study, of which 79 were NPSLE
239 and 142 were non-NPSLE. Supplementary Table S3 includes demographic and clinical data for
240 the two subgroups. No significant differences were found between the two groups in
241 demographic and clinical variables.

242 **3.2 Cluster analysis**

243 The cluster analysis was performed on all patients and yielded in five distinct clusters (Figure
244 2): cluster 1 ($n=52$) is mainly assigned to the forceps major and to lesser extent to the left and
245 right inferior fronto-occipital fasciculus; cluster 2 ($n=57$) mainly to the right anterior thalamic
246 radiation and to lesser extent to the forceps minor and the right inferior fronto-occipital
247 fasciculus; cluster 3 ($n=23$) to the forceps minor; cluster 4 ($n=30$) to the left anterior thalamic
248 radiation and to lesser extent to the forceps minor and the right anterior thalamic radiation;
249 and cluster 5 ($n=24$) was more heterogeneous in terms of location in WM tracts but it could be
250 mainly assigned to the right inferior fronto-occipital fasciculus. A total of 35 patients (8 NPSLE,
251 27 non-NPSLE) with no WMH were excluded from cluster analysis. The lesion frequency maps
252 (Figure 3) show the WMH location probability in each cluster.

253 Patient age, volume and number of WMH lesions were statistically significantly different across
254 clusters ($p=0.005$, $p=0.008$ and $p=0.003$ respectively). After correction for multiple testing,
255 patient age was significantly higher ($p=0.002$) in cluster 5 compared to patients without
256 detectable WMH. WMH volume and number in cluster 4 was significantly higher than in cluster
257 3 ($p < 0.001$) and number of lesions was significantly higher in cluster 2 compared to cluster 3
258 ($p=0.001$) (Supplementary Table S4).

260 **3.3 Performance evaluation of the cluster analysis**

261 The cluster analysis was evaluated through a consensus of two different methods. The
262 Silhouette coefficient and Calinski-Harabaz index showed a clear peak using five clusters
263 (Figure 4). Although the Silhouette coefficient seems to increase with higher cluster size (with
264 local maximum for 5 clusters), the Calinski-Harabaz index sharply decreases with increasing
265 number of clusters, therefore $n(\text{clusters}) = 5$ was chosen for best performance.

266 **3.4 Sensitivity analysis**

269 Sensitivity analysis was implemented in three different ways. The first sensitivity analysis was
270 performed separately on each of the two subgroups of SLE patients: NPSLE and non-NPSLE.
271 This resulted in an overlap of the number of the same patients included in a certain cluster of
272 83% for the NPSLE group and 85% for the non-NPSLE group, when compared to the main
273 analysis where all SLE patients were included. The cluster analysis on NPSLE patients resulted
274 in 6 clusters. Similarly to the cluster analysis performed on the entire group, clusters 1, 2, 3 and
275 5 were mainly assigned to specific WM tracts: forceps major, right anterior thalamic radiation,
276 forceps minor and left anterior thalamic radiation, respectively. Cluster 4 consisted of two
277 subjects and was attributed to the left inferior fronto-occipital fasciculus. Cluster 6 was more
278 heterogeneous in terms of WM tract location and was comparable to cluster 5 of the main
279 analysis (Figure 5). The corresponding NP manifestations in the NPSLE subgroup showed no
280 correlation with the unveiled clusters (Supplementary Figure S2). The cluster analysis on non-
281 NPSLE patients revealed 5 clusters. Clusters 1, 2, 3 and 4 could be mainly assigned to the same
282 specific WM tracts identified in the main cluster analysis: forceps major, forceps minor, right
283 anterior thalamic radiation and left anterior thalamic radiation, respectively. Similar to the
284 NPSLE subgroup clustering, cluster 5 was more heterogeneous in terms of WM tract location
285 and comparable to cluster 5 of the main analysis (Figure 5).

286 The second sensitivity analysis was performed on each site separately (Figure 6). Compared to
287 the main analysis, the overlap of the same patients in the certain clusters resulted in 93% for
288 the Lund cohort and 87% for the Leiden cohort. The four clusters revealed from clustering the
289 Lund cohort separately, can be assigned to the right anterior thalamic radiation, the forceps
290 minor, the forceps major, similar to the main analysis, and a heterogeneous cluster in terms of
291 the affected tracts, similar to the cluster 5 in the main analysis. The five clusters revealed from
292 clustering the Leiden cohort separately can be assigned to the forceps major, the forceps minor
293 and the left and right anterior thalamic radiation, similar to the main analysis, and a
294 heterogeneous cluster in terms of the affected tracts, similar to cluster 5 in the main analysis.

295 The third and last sensitivity analysis was performed on the entire SLE population using as
296 regressors the site and the significant differences between the cohorts: sex, type of FLAIR, age,
297 disease duration, SDI-score, SLEDAI-2k-score and the WMH total volume using a general
298 linear model (GLM). The resulting clusters showed an overlap of 90% with those obtained by
299 the main analysis (Figure 7). Cluster 1 to 4 could be mainly assigned to specific WM tracts:
300 forceps major, right anterior thalamic radiation, forceps minor and left anterior thalamic
301 radiation, respectively. Cluster 5 was more heterogeneous in terms of WM tract location and
302 was comparable to cluster 5 of the main analysis.

303

304 **3.5 Volumetric analysis of the WMH**

305 The distributions of the WMH volumes on each WM tract for each cluster on the total SLE
306 population are given in Supplementary Table S5. With the exception of the right corticospinal
307 tract and the left cingulum cingulate gyrus, statistically significant differences in WMH
308 volumes were found in all WM tracts, across all five clusters. The main WM tract assigned to
309 each cluster shows also the highest volume.

310 The WMH volume was significantly higher in NPSLE patients compared to non-NPSLE
311 patients in the right anterior thalamic radiation ($p=0.024$), in the right inferior fronto-occipital
312 fasciculus ($p=0.010$), in the right inferior longitudinal fasciculus ($p=0.041$) and in the right
313 uncinata fasciculus ($p=0.033$) (Supplementary Table S6).

314

315

316

317 **4. DISCUSSION**

318 We developed a fully automated method to unveil WMH pattern in SLE patients experiencing
319 NP events. We applied this method on a two-center dataset of SLE patients. Our method
320 detected five robust and distinct clusters, characterized by the involvement of the forceps major,
321 forceps minor as well as the left and right anterior thalamic radiation and the right inferior
322 fronto-occipital fasciculus (Figures 2 and 3). Our results are consistent across the two
323 subgroups, NPSLE and non-NPSLE patients (Figure 4). Despite the heterogeneity of the
324 disease, our results are consistent across both sites (Figure 6) and are not affected by the clinical
325 and radiological differences between the two cohorts (Figure 7). Differences in volume and
326 number of WMHs were observed between the clusters and subgroups as presented in the
327 Supplementary Tables S5 and S6.

328 Cluster analysis has been applied successfully to identify distinct clusters based on coarse
329 location of WMH in other brain disorders, such as arterial disease³⁶ and postoperative
330 delirium³⁷. So far, unsupervised machine learning approaches based on structural MRI
331 information were not explored in research involving SLE patients^{5,6}. To the best of our
332 knowledge, the work we present here is the first machine learning analysis that focuses on brain
333 features gauged by MRI in SLE. Compared to previous studies^{16,17}, in our developed method
334 the WMH were detected and assigned to WM tracts automatically by using a well-established
335 lesion segmentation algorithm and further processed by publicly available software³⁸. Further,
336 the L2-normalization highlighted the underlying WMH pattern for each patient by reducing the
337 impact of the total WMH burden and harmonizing the two-sites dataset. These steps, in
338 combination with a machine learning technique unveiled a consistent spatial pattern of the
339 mainly affected WM tracts. Few studies applied cluster analysis in SLE but those are based on
340 clinical features, such as demographic³⁹, genetic⁴⁰ and autoantibodies⁴¹ data.. In contrast, our
341 developed approach focuses on MRI brain features which could provide a basis to link
342 neuroimaging findings to clinical symptoms.

343
344 Several studies in other diseases, such as Alzheimer's disease and MS showed the importance
345 to categorize spatially WMH to the link with neuropsychological impairment^{12,13}. Previous
346 studies in SLE patients showed higher prevalence of WMH on specific WM tracts^{16,17,42,43,44}.
347 However, manual segmentation of the WMH and their subsequent ways to assign WMH to
348 specific WM tracts may have influenced the reproducibility of the study and make it difficult
349 to compare them with our approach. Furthermore, these studies included also SLE patients
350 without any NP syndromes, a subgroup which was not included in the present study^{16,17}. Our
351 method identified a set of WM tracts with the highest lesion volume, which seem to be those
352 most significantly involved in our SLE patients experiencing NP manifestations. In healthy
353 elderly, WMH on tracts adjacent to the frontal horns of lateral ventricles, such as the left and
354 right anterior thalamic radiation, are associated with worse performance in executive
355 function^{45,46} and planning complex behavior⁴⁶. Indeed, decrease of complex planning behavior
356 performance is shown in SLE patients⁴⁷. Microstructural WM abnormalities in forceps minor
357 are higher in patient with Schizophrenia compared to controls⁴⁸ and are related to depression
358 and fatigue in MS⁴⁹. Furthermore, both anterior thalamic radiation and forceps minor are linked
359 to cognitive impairment in patients with SVD⁵⁰. Since the importance of the frontal WM tracts
360 in cognition and psychiatric disorder, future studies are needed to fully understand the role that
361 the tracts we found in this study may play in the performance of NPSLE patients.

362 All SLE patients, except those without detectable WMH, were included in the cluster analysis
363 without considering the subgroups or the affiliation to cohorts. The attribution process of the
364 NP events is difficult since the nature of NP syndromes is heterogeneous (can vary from
365 headache and seizures to anxiety and psychosis)⁹ and there are large differences in the NP
366 attribution across studies (between 37% and 95%)⁴. It has been demonstrated that

367 misclassification of NP events may occur in clinical practice with an over attribution of NP to
368 the disease (NPSLE)⁵¹. Several challenges are related to the diagnostic procedure of NPSLE.
369 First, SLE is categorized as a rare disease (prevalence 1-5/10 000, source www.orpha.net) and
370 many SLE studies suffer from small sample sizes^{5,52}, hampers to draw conclusions regarding
371 the reliability and robustness of results. To overcome this problem, we performed a two site
372 study. Second, the absence of biomarkers (radiological or laboratory) reliable enough in the
373 diagnostic process make it difficult to create a link between radiological findings and clinical
374 symptoms (clinic-radiological paradox)⁵.

375 In this study we could not find an association between the NP manifestations and the clusters
376 in the NPSLE subgroup. We assume that the reason for this lies in the strong variability of NP
377 manifestations between the two clinical cohorts (Supplementary Figure S2) and in the highly
378 heterogenous nature of NP syndromes. Even though NPSLE patients showed higher WMH
379 volume in some WM tracts compared to non-NPSLE patients, the cluster analysis showed that
380 the WM tracts most affected by WMH are similar in both subgroups. This suggests that location
381 and pattern of WMH have no correlation with NPSLE diagnosis and attribution to the disease.
382 Therefore, location may give a new important information about WMH in SLE. Describing
383 WMH only in terms of volume or number may not give enough information about etiology but
384 in severity. Furthermore, despite the heterogeneity of the NP events within each site and the
385 diagnostic, clinical and radiological variability across sites, our results appeared to be robust
386 and stable. This is the first comprehensive study to examine WMH in SLE that assesses a broad
387 categorization of WMH in terms of load, location and volume using a fully automated method
388 in two site cohort.

389 Our work is not without limitations. Some clusters identified by our method comprise a low
390 number of patients. This is expected, since SLE is a rare disease, and even with our effort to
391 increase the patient population by merging data from two centers, the overall number of patients
392 remains small compared to similar studies performed in more common diseases. A significant
393 limitation of this study is the lack of a subgroup of SLE patients without NP symptoms. The
394 lack of such a group stems from the retrospective nature of this study and the lack of availability
395 of imaging data within our database. Recruiting such a cohort in future studies will undoubtedly
396 strengthen any conclusion regarding the link between spatial distribution of brain abnormalities
397 and NP symptoms in SLE, as it has been repeatedly shown that patients with SLE without NP
398 also exhibit brain abnormalities, albeit to a lesser extent⁵³. Further, the focus on structural MRI
399 information omits the possible impact of clinical features, such as the presence of clinical
400 activity, antiphospholipid antibodies positivity as well as cardiovascular risk factors and other
401 factors that were not included in the present analysis. This is a limitation of this study, and
402 future multicenter studies would benefit from incorporating such data in the analysis.
403 Additionally, patients for which automated detection of WMH yielded no positive results, were
404 not included in our analysis. This study was retrospectively performed in prospective cohorts,
405 therefore differences in MRI protocol, diagnosis definition, and clinical data are present and
406 can contribute to biases between groups and to an increased variance. The MRI sequences, and
407 in particular the FLAIR sequences, were different between sites. However, in all our analyses,
408 subgroups, cohorts and 3D FLAIR scans were not predominant in a specific cluster. Differences
409 in NP attribution and diagnosis between the two sites, could have had an effect on the results.
410 However, the sensitivity analysis we performed show that the WMH patterns obtained by our
411 clustering strategy are robust even when SLE subgroups and cohorts are clustered separately,
412 or when corrected for significant clinical and radiological differences.

413 To conclude, we developed a method based on an unsupervised machine learning approach and
414 identified a WMH pattern which was consistent in a two-site cohort. With our approach, we
415 provided a fully automated standardized method to identify tract-based WMH patterns. The

416 identification of affected WM tracts via the clustering algorithm was robust, despite
417 heterogeneity of the NP events and their association with the disease. Allocation of the WMH
418 burden to the most affected WM tracts could help investigate the link between radiological
419 findings and clinical symptoms in SLE patients with NP manifestations. In a future study an
420 association between pathogenesis, overall phenotypes and even genetics would be interesting
421 to explore.

422

423

424 **REFERENCES**

- 425
- 426 1. Debette, S. & Markus, H. S. The clinical importance of white matter hyperintensities
427 on brain magnetic resonance imaging: Systematic review and meta-analysis. *BMJ* **341**,
428 288 (2010).
- 429 2. Wardlaw, J. M. *et al.* Neuroimaging standards for research into small vessel disease
430 and its contribution to ageing and neurodegeneration. *Lancet Neurol.* **12**, 822–838
431 (2013).
- 432 3. Pantoni, L. Cerebral small vessel disease: from pathogenesis and clinical characteristics
433 to therapeutic challenges. *The Lancet Neurology* **9**, 689–701 (2010).
- 434 4. Govoni, M. *et al.* The diagnosis and clinical management of the neuropsychiatric
435 manifestations of lupus. *J. Autoimmun.* **74**, 41–72 (2016).
- 436 5. Magro-Checa, C., Steup-Beekman, G. M., Huizinga, T. W., van Buchem, M. A. &
437 Ronen, I. Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic
438 Lupus Erythematosus: Where Do We Stand, Where To Go? *Front. Med.* **5**, (2018).
- 439 6. Hanly, J. G., Kozora, E., Beyea, S. D. & Birnbaum, J. Review: Nervous System
440 Disease in Systemic Lupus Erythematosus: Current Status and Future Directions.
441 *Arthritis Rheumatol.* **71**, 33–42 (2019).
- 442 7. Ainiala, H., Loukkola, J., Peltola, J., Korpela, M. & Hietaharju, A. The prevalence of
443 neuropsychiatric syndromes in systemic lupus erythematosus. *Neurology* **57**, 496–500
444 (2001).
- 445 8. Gladman, D. D. *et al.* The Systemic Lupus International Collaborating
446 Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for systemic
447 lupus erythematosus international comparison. *J. Rheumatol.* **27**, 373–376 (2000).
- 448 9. Hanly, J. G. Diagnosis and management of neuropsychiatric SLE. *Nat. Rev.*
449 *Rheumatol.* **10**, 338–347 (2014).
- 450 10. Bortoluzzi, A. *et al.* Development and validation of a new algorithm for attribution of
451 neuropsychiatric events in systemic lupus erythematosus. *Rheumatol. (United*
452 *Kingdom)* **54**, 891–898 (2014).
- 453 11. Preziosa, P. *et al.* Structural MRI correlates of cognitive impairment in patients with
454 multiple sclerosis: A Multicenter Study Structural MRI Correlates of Cognitive
455 Impairment in Patients With Multiple Sclerosis: A Multicenter Study Cognitive
456 Impairment and Brain Damage in . *Hum. Brain Mapp.* **37**, 1627–1644 (2016).
- 457 12. Meijer, K. A., Steenwijk, M. D., Douw, L., Schoonheim, M. M. & Geurts, J. J. G.
458 Long-range connections are more severely damaged and relevant for cognition in
459 multiple sclerosis. *Brain* **143**, 150–160 (2020).
- 460 13. Taylor, A. N. W. *et al.* Tract-specific white matter hyperintensities disrupt neural
461 network function in Alzheimer’s disease. *Alzheimer’s Dement.* **13**, 225–235 (2017).
- 462 14. Ghaznawi, R., Geerlings, M., Jaarsma-Coes, M., Hendrikse, J. & de Bresser, J.
463 Association of White Matter Hyperintensity Markers on MRI and Long-term Risk of
464 Mortality and Ischemic Stroke. *Neurology* 10.1212/WNL.0000000000011827 (2021).
465 doi:10.1212/wnl.0000000000011827
- 466 15. Inglese, F. *et al.* Different phenotypes of neuropsychiatric systemic lupus
467 erythematosus are related to a distinct pattern of structural changes on brain MRI. *Eur.*
468 *Radiol.* (2021). doi:10.1007/s00330-021-07970-2
- 469 16. Ramirez, G. A. *et al.* Quantitative MRI adds to neuropsychiatric lupus diagnostics.
470 *Rheumatology* 1–11 (2020). doi:10.1093/rheumatology/keaa779
- 471 17. Shastri, R. K. *et al.* MR Diffusion Tractography to Identify and Characterize
472 Microstructural White Matter Tract Changes in Systemic Lupus Erythematosus
473 Patients. *Acad. Radiol.* **23**, 1431–1440 (2016).

- 474 18. Danelakis, A., Theoharis, T. & Verganelakis, D. A. Survey of automated multiple
475 sclerosis lesion segmentation techniques on magnetic resonance imaging. *Comput.*
476 *Med. Imaging Graph.* **70**, 83–100 (2018).
- 477 19. Caligiuri, M. E. *et al.* Automatic Detection of White Matter Hyperintensities in Healthy
478 Aging and Pathology Using Magnetic Resonance Imaging: A Review.
479 *Neuroinformatics* **13**, 261–276 (2015).
- 480 20. Heinen, R. *et al.* Performance of five automated white matter hyperintensity
481 segmentation methods in a multicenter dataset. *Scientific Reports* **9**, 1–12 (2019).
- 482 21. de Sitter, A. *et al.* Performance of five research-domain automated WM lesion
483 segmentation methods in a multi-center MS study. *Neuroimage* **163**, 106–114 (2017).
- 484 22. Vanderbecq, Q. *et al.* Comparison and validation of seven white matter hyperintensities
485 segmentation software in elderly patients. *NeuroImage Clin.* **27**, (2020).
- 486 23. Zirkzee, E. J. M. *et al.* Prospective study of clinical phenotypes in neuropsychiatric
487 systemic lupus erythematosus; Multidisciplinary approach to diagnosis and therapy. *J.*
488 *Rheumatol.* **39**, 2118–2126 (2012).
- 489 24. Monahan, R. C. *et al.* Mortality in patients with systemic lupus erythematosus and
490 neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in
491 the Netherlands. *Lupus* **29**, 1892–1901 (2020).
- 492 25. Hanly, J. G. *et al.* Neuropsychiatric events at the time of diagnosis of systemic lupus
493 erythematosus: An international inception cohort study. *Arthritis Rheum.* **56**, 265–273
494 (2007).
- 495 26. Liang, M. H. *et al.* The American College of Rheumatology nomenclature and case
496 definitions for neuropsychiatric lupus syndromes. *Arthritis Rheum.* **42**, 599–608
497 (1999).
- 498 27. Hochberg, M. C. Updating the American College of Rheumatology revised criteria for
499 the classification of systemic lupus erythematosus. *Arthritis Rheum.* **40**, 1725 (1997).
- 500 28. Gladman, D. D., Ibañez, D. & Urowltz, M. B. Systemic lupus erythematosus disease
501 activity index 2000. *J. Rheumatol.* **29**, 288–291 (2002).
- 502 29. Petri, M. *et al.* Derivation and validation of the systemic lupus international
503 collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis*
504 *Rheum.* **64**, 2677–2686 (2012).
- 505 30. Ward, J. H. Hierarchical Grouping to Optimize an Objective Function. *J. Am. Stat.*
506 *Assoc.* **58**, 236–244 (1963).
- 507 31. Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *J. Mach. Learn. Res.* **12**,
508 2825–2830 (2012).
- 509 32. Rousseeuw, P. J. Silhouettes: A graphical aid to the interpretation and validation of
510 cluster analysis. *J. Comput. Appl. Math.* **20**, 53–65 (1987).
- 511 33. Caliński, T. & Harabasz, J. A Dendrite Method For Cluster Analysis. *Commun. Stat.* **3**,
512 1–27 (1974).
- 513 34. Virtanen, P. *et al.* SciPy 1.0: fundamental algorithms for scientific computing in
514 Python. *Nat. Methods* **17**, 261–272 (2020).
- 515 35. Seabold, S. & Perktold, J. Statsmodels: Econometric and Statistical Modeling with
516 Python. in 92–96 (2010). doi:10.25080/Majora-92bf1922-011
- 517 36. Jaarsma-Coes, M. G. *et al.* MRI phenotypes of the brain are related to future stroke and
518 mortality in patients with manifest arterial disease: The SMART-MR study. *J. Cereb.*
519 *Blood Flow Metab.* (2018). doi:10.1177/0271678X18818918
- 520 37. Kant, I. M. J. *et al.* Preoperative MRI brain phenotypes are related to postoperative
521 delirium in older individuals. *Neurobiol. Aging* **101**, 247–255 (2021).
- 522 38. Schmidt, P. *et al.* An automated tool for detection of FLAIR-hyperintense white-matter
523 lesions in Multiple Sclerosis. *Neuroimage* **59**, 3774–3783 (2012).

- 524 39. Pego-Reigosa, J. M. *et al.* Relationship between damage clustering and mortality in
525 systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in
526 a large cohort from the Spanish Society of Rheumatology Lupus Registry. *Rheumatol.*
527 *(United Kingdom)* **55**, 1243–1250 (2016).
- 528 40. Zollars, E. *et al.* Clinical application of a modular genomics technique in systemic
529 lupus erythematosus: Progress towards precision medicine. *Int. J. Genomics* **2016**,
530 (2016).
- 531 41. To, C. H. & Petri, M. Is antibody clustering predictive of clinical subsets and damage
532 in systemic lupus erythematosus? *Arthritis Rheum.* **52**, 4003–4010 (2005).
- 533 42. Nystedt, J. *et al.* Altered white matter microstructure in lupus patients: A diffusion
534 tensor imaging study. *Arthritis Res. Ther.* **20**, 1–11 (2018).
- 535 43. Costallat, B. L. *et al.* Brain diffusion tensor MRI in systematic lupus erythematosus: A
536 systematic review. *Autoimmun. Rev.* **17**, 36–43 (2018).
- 537 44. Jung, R. E. *et al.* White matter correlates of neuropsychological dysfunction in
538 systemic Lupus Erythematosus. *PLoS One* **7**, 1–6 (2012).
- 539 45. Lampe, L. *et al.* Lesion location matters: The relationships between white matter
540 hyperintensities on cognition in the healthy elderly. *J. Cereb. Blood Flow Metab.* **39**,
541 36–43 (2017).
- 542 46. Niida, R. *et al.* Aberrant Anterior Thalamic Radiation Structure in Bipolar Disorder: A
543 Diffusion Tensor Tractography Study. *Front. Psychiatry* **9**, 522 (2018).
- 544 47. Calderón, J. *et al.* Impact of cognitive impairment, depression, disease activity, and
545 disease damage on quality of life in women with systemic lupus erythematosus. *Scand.*
546 *J. Rheumatol.* **46**, 273–280 (2017).
- 547 48. KA, C. *et al.* Mean diffusivity and fractional anisotropy as indicators of disease and
548 genetic liability to schizophrenia. *J. Psychiatr. Res.* **45**, 980–988 (2011).
- 549 49. C, G. *et al.* Forceps minor damage and co-occurrence of depression and fatigue in
550 multiple sclerosis. *Mult. Scler.* **20**, 1633–1640 (2014).
- 551 50. M, D. *et al.* Strategic role of frontal white matter tracts in vascular cognitive
552 impairment: a voxel-based lesion-symptom mapping study in CADASIL. *Brain* **134**,
553 2366–2375 (2011).
- 554 51. Magro-Checa, C. *et al.* Value of multidisciplinary reassessment in attribution of
555 neuropsychiatric events to systemic lupus erythematosus: Prospective data from the
556 Leiden NPSLE cohort. *Rheumatol. (United Kingdom)* **56**, 1676–1683 (2017).
- 557 52. Postal, M., Lapa, A. T., Reis, F., Rittner, L. & Appenzeller, S. Magnetic resonance
558 imaging in neuropsychiatric systemic lupus erythematosus: Current state of the art and
559 novel approaches. *Lupus* **26**, 517–521 (2017).
- 560 53. Ercan, E. *et al.* A multimodal MRI approach to identify and characterize
561 microstructural brain changes in neuropsychiatric systemic lupus erythematosus.
562 *NeuroImage Clin.* **8**, 337–344 (2015).
- 563
- 564

565 **AUTHOR CONTRIBUTIONS**

566 **TR:** Software, Data curation, Formal analysis, Visualization, Roles/Writing – original draft.
567 **FI:** Data curation, Visualization, Formal analysis, Roles/Writing – original draft. **JdB:**
568 Roles/Writing – original draft, Validation. **PM:** Data curation, Software, Writing – review and
569 editing. **AJ:** Resources, Validation, Writing – review and editing. **AB:** Resources, Validation,
570 Writing – review and editing. **MN:** Conceptualization, Validation, Writing – review and
571 editing. **LK:** Conceptualization, Validation, Writing – review and editing. **JL:** Data curation,
572 Software, Writing – review and editing. **GMSB:** Resources, Validation, Writing – review and
573 editing. **TWJH:** Resources, Validation, Writing – review and editing. **MAvB:** Validation,
574 Writing – review and editing, **OS:** Conceptualization, Software, Writing – review and editing.
575 **IR:** Funding acquisition, Supervision, Project administration, Roles/Writing – original draft.
576 **PCS:** Funding acquisition, Supervision, Project administration, Roles/Writing – original draft.
577

578 **DATA AVAILABILITY STATEMENT**

579 Under General Data Protection Regulation (GDPR) restrictions, the MRI and other patient data
580 cannot be made publicly available. Each of the two sites involved in this study (Lund
581 University, Leiden University Medical Center) can share anonymized data with individual sites
582 following an appropriate data transfer agreement (DTA). Under such agreement, each site
583 (Lund, Leiden) will share only their own data with the signing site. Requests for DTA should
584 be sent to Pia Sundgren (Lund University, pia.sundgren@med.lu.se) or Itamar Ronen (Leiden
585 University Medical Center, i.ronen@lumc.nl).

586 The code used for data preprocessing and cluster analysis can be found in the following GitHub
587 repository: https://github.com/TheoRum/manuscript_WMH_SLE
588

589 **CONFLICT OF INTEREST STATEMENT**

590 The authors declare that the research was conducted in the absence of any commercial or
591 financial relationships that could be construed as a potential conflict of interest.
592

593 **ACKNOWLEDGEMENTS**

594 The study was supported by funding by Regional Research funds (RegSkane 625631), SUS
595 Foundation and Donation funds (PCS), Alfred Österlund foundation (PCS), Swedish
596 Rheumatism Association R-56371 (PCS), King Gustaf V's 80-year foundation (FAI-2017-0341
597 and FAI-2019-0559) (PCS).

598 The funding sources had no involvement in the study design, in the collection, analysis and
599 interpretation of data, in the writing of the report and in the decision to submit the article for
600 publication.
601

602 **ETHICS STATEMENT**

603 All patients included in this study signed informed consent and it was approved by the Leiden-
604 The Hague-Delft, The Netherlands, ethics approval committee (registration number P07.177)
605 and the Regional Ethical Review Board in Lund, Sweden (#2012/4, #2014/748).
606
607
608

609 **TABLE**

610

611 **Table 1. Demographic and clinical data across the two site cohorts.** Data are represented as
 612 number (percentage) or median (10-90 percentile). Differences between Leiden and Lund
 613 cohort are expressed in p-value and calculated for nominal variables with Chi-square tests (sex)
 614 and for continuous variables, based on their not-normally distribution, with Mann-Whitney U
 615 tests.

616 NPSLE= neuropsychiatric systemic lupus erythematosus; SDI= systemic lupus international
 617 collaborating clinics damage index; SLEDAI-2K= systemic lupus erythematosus disease
 618 activity index 2000; ACR= American College of Rheumatology.

619

620 *= p value<0.05


621

	Leiden	Lund	Leiden vs Lund p-value
No. of subjects	152	69	
Non-NPSLE	115	27	
NPSLE	37	42	
FLAIR 3D	53 (34%)	0 (0%)	
sex female	138 (90%)	69 (100%)	0.021*
age	42 (25-58)	37.5 (24-47)	0.002*
disease duration (years)			
non-NPSLE	6.6 (0.4-17.4)	9.5 (1.0-20.0)	0.087
NPSLE	2.5 (0.1-17.5)	10.0 (1.0-22.6)	0.001*
age of disease onset			
non-NPSLE	33.1 (18.6-52.8)	24.5 (15.5-37.0)	0.000*
NPSLE	31.5 (20.3-51.1)	24.0 (15.0-37.8)	0.006*
SDI score			
non-NPSLE	0 (0-2)	0 (0-2)	0.044*
NPSLE	1 (0-2)	0 (0-2)	0.045*
SLEDAI2k score			
non-NPSLE	4 (0-10)	2 (0-4)	0.006*
NPSLE	6 (0-20)	2 (0-4)	0.000*
ACR criteria			
non-NPSLE	5 (3.4-7.0)	6 (4.6-8.0)	0.003*
NPSLE	5 (4.0-6.4)	5 (4.0-7.0)	0.094
WMH volume in ml			
non-NPSLE	0.102 (0.0-2.3)	0.018 (0.0-0.3)	0.031*
NPSLE	0.353 (0.0-6.2)	0.057 (0.0-0.3)	0.000*
WMH number			
non-NPSLE	2 (0.0-12.8)	1 (0.0-6.0)	0.073
NPSLE	4 (0.0-16.8)	2 (0.0-6.8)	0.000*


622

623

624 **FIGURES**
625




626
627 **Figure 1. Preprocessing workflow.** Workflow of the fully automated approach. 3D-FLAIR
628 images are reoriented and co-registered to the T₁-weighted (T1w) before WMH segmentation.
629 White matter hyperintensities (WMH) segmentation is performed with the Lesion
630 Segmentation Toolbox-Lesion Growth Algorithm (LST-LGA) using T1w and FLAIR images.
631 The volume and number of WMH are extracted from the WMH maps in T1-space. The WMH
632 probability maps are transformed to Montreal Neurological Institute (MNI) space by applying
633 the transformation from the T1w images. Those maps are masked by the Johns Hopkins
634 University (JHU) white matter (WM) probability atlas to obtain the tract specific WMH
635 volumes. To quantitatively assign WMH to specific WM tracts the probability values of
636 superimposed voxels on the lesion map and the WM tract are multiplied and the resulting
637 product is summed over the entire tract.
638 FLAIR= fluid-attenuated inversion recovery; FSL= FMRIB Software Library; FLIRT= Linear
639 Image Registration Tool; BET= Brain Extraction Tool; ANTs= Advanced Normalization Tools
640
641




642
643
644
645
646
647
648
649
650
651
652

Figure 2. Cluster analysis on the entire SLE cohort. Heatmaps showing the 5 different MRI subtypes after the hierarchical clustering with the L2-normalization was performed. Subjects are shown on the x-axis and the Johns Hopkins University (JHU) white matter probability atlas tracts on the y-axis. The horizontal bars at the top show additional information: Leiden cohort (brown) complemented by the Lund cohort, 3D-FLAIR (pink) complemented by 2D-FLAIR, non-NPSLE (blue), NPSLE (red). FLAIR= fluid-attenuated inversion recovery; NPSLE= neuropsychiatric systemic lupus erythematosus.




653
654 **Figure 3. Lesion frequency map for each cluster in MNI-space.** WMH in cluster 1 can be
655 mainly assigned to Forceps Major, cluster 2 to right Anterior Thalamic Radiation, cluster 3 to
656 Forceps Minor and 4 to the left Anterior Thalamic Radiation. Cluster 5 shows a high WMH
657 burden and can be assigned to the right inferior fronto-occipital fasciculus. Clusters are shown
658 as lesion probabilities from 0.0 to 0.5 (color scale on the right). The main WMH corresponding
659 to specific WM tracts (copper color) are emphasized with red arrows.
660
661




662
663
664
665
666
667
668
669
670
671

Figure 4. Clustering performance evaluation. To determine the optimal number of clusters in the hierarchical cluster analysis a consensus of two different methods were used. The mean Silhouette Coefficient (on the left) is calculated over mean intra-cluster distance divided by the minimal inter-cluster distance to the nearest cluster. Positive values indicate a dense clustering whereas negative an incorrect clustering. The Calinski-Harabaz index (on the right) is the ratio of the sum of distances squared between and within the clusters. A high index indicated a dense and well separated cluster. Both methods indicate an optimal number of clusters of 5.



672
673
674
675
676
677
678
679
680


Figure 5. Sensitivity analysis on NPSLE and non-NPSLE patients. Cluster analysis on NPSLE patients (top) and on non-NPSLE patients (bottom). The horizontal bars at the top show additional information: Leiden cohort (brown) complemented by the Lund cohort, 3D-FLAIR (pink) complemented by 2D-FLAIR, non-NPSLE (blue), NPSLE (red). FLAIR= fluid-attenuated inversion recovery; NPSLE= neuropsychiatric systemic lupus erythematosus.



681
 682 **Figure 6. Sensitivity analysis on each cohort separately.** Cluster analysis on Lund (top) and
 683 Leiden cohort (bottom). The horizontal bars at the top show additional information: Leiden
 684 cohort (brown) complemented by the Lund cohort, 3D-FLAIR (pink) complemented by 2D-
 685 FLAIR, non-NPSLE (blue), NPSLE (red).

686 FLAIR= fluid-attenuated inversion recovery; NPSLE= neuropsychiatric systemic lupus
 687 erythematosus

688
 689



690
691
692
693
694
695
696
697
698
699
700

Figure 7. Sensitivity Analysis using GLM. Cluster analysis on the entire SLE cohort performed after L2 normalization and GLM model to correct for cohort, type of FLAIR, sex, age, disease duration. SDI-score, SLEDAI-2k-score and WMH total volume. The horizontal bars at the top show additional information: Leiden cohort (brown) complemented by the Lund cohort, 3D-FLAIR (pink) complemented by 2D-FLAIR, non-NPSLE (blue), NPSLE (red). GLM= General linear model; FLAIR= fluid-attenuated inversion recovery; NPSLE= neuropsychiatric systemic lupus erythematosus; SDI= systemic lupus international collaborating clinics damage index; SLEDAI-2K = systemic lupus erythematosus disease activity index 2000.